TrialOrphanet journal of rare diseases2025

A phase 2 randomized, double-blind trial of ART-001, a selective PI3Kα inhibitor, for the treatment of slow-flow vascular malformations.

Michio Ozeki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.